Evidence map›Paper›PMID 38860750›Full record

SynthesisImmunity, inflammation and disease2024

Tumor necrosis factor-α polymorphism and risk of primary nephrotic syndrome: A case-control study and meta-analysis.

Rongfen Zhao, Yufeng Wang, Yihua Zhou, Wu Fan, Haiyan Yin

Abstract readMeta-Analysis
In one paragraph

Synthesis in Immunity, inflammation and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rongfen ZhaoDepartment of Clinical Laboratory, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, China.
Yufeng WangDepartment of Clinical Laboratory, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, China.
Yihua ZhouDepartment of Clinical Laboratory, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, China.
Wu FanDepartment of Clinical Laboratory, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, China.
Haiyan YinDepartment of Clinical Laboratory, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, China.ORCID 0009-0001-4068-8968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current study aims to explore the relationship between tumor necrosis factor-α (TNF-α) polymorphism and the risk of primary nephrotic syndrome (PNS).

methodsA total of 250 PNS patients were selected for this study, as well as 300 volunteers serving as the control group. TNF-α polymorphism were assessed using the polymerase chain reaction-restriction fragment length polymorphism method. In addition, a meta-analysis was conducted to analyze previously published literature on this topic.

resultsNo significant differences were observed in the genotypes frequency or alleles frequency among the study populations. Meta-analysis results revealed a positive association between TNF-α rs1800629 polymorphism and allele contrast in African populations (p = 0), homozygote comparison (p = .007), heterozygote comparison (p = .026), recessive genetic model (p = .011), and dominant genetic model (p = .000).

conclusionsTNF-α rs1800629 polymorphism does not appear to confer any increased risk for PNS.

Indexed as

Genetic Predisposition to DiseaseNephrotic SyndromePolymorphism, Single NucleotideTumor Necrosis Factor-alphaAdultAllelesCase-Control StudiesFemaleGene FrequencyGenotypeHumansMaleMiddle AgedRisk FactorsTumor Necrosis Factor-alphagene polymorphismmeta‐analysisnovel markerprimary nephrotic syndromeTNF‐α

Identifiers

PMID38860750
PMCPMC11165685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.